Pharmaceutical Formulation Intermediates (PFIs)

Granules pioneered the concept of commercializing PFIs or Pre formulation Ingredients, a conception for large-volume drug molecules within the pharmaceutical production.

We entered into this business segment in the early 90s, following an insight that most finished dosage manufacturers were not efficiently producing PFIs. Manufacturers were granulating but could not derive operational efficiencies. They focused on dozens of products or only created large-volume products in limited quantities, each batch of which was processed & tested individually.
Consequently, it increased the overall cost to the manufacturers and in turn the customers, which finally resulted in an increased cost of product to the end consumer. This also pulled down the overall return from the manufacturers’ ‘investments,’ especially because PFI manufacturing accounts for 80% of the total cost of a finished dosage.



First Slide

Granules India offers PFIs that are meant to be taken from ‘drum to hopper’
by our customers. The pre-formulation ingredients are taken directly from the drums to a hopper, where they are directly compressed into tablets.



Benefits


Reduces Vendor Development Cost

Reduces Vendor Development Cost

Customers save a significant amount on vendor development costs, since they need to deal with only one vendor for various materials and processes, required to manufacture PFIs.

Simplifies Supply Chain Management

Simplifies Supply Chain Management

PFIs simplify supply chain complexities for customers, since they need to deal with only one vendor. Subsequently, their working capital costs also decline.

Lowers Testing
Costs

Lowers Testing
Costs

Customers conduct a single test, resulting in significant savings. Our volume-based manufacturing and bigger batch size (six ton) ensure consistency in the quality of deliverables to the customers.

Saves Technical
Resources

Saves Technical
Resources

Our ability to manufacture complex PFIs allows customers to avoid large expenditures on pre-formulation studies and process development.

Reduces Capital
Expenditure

Reduces Capital Expenditure

Setting up a PFI facility comprises over 80% of the total investments in a normal oral solid dosage manufacturing facility. Our expertise to deliver PFI allows customers to stay asset light.

Provides Desired Release Properties

Provides Desired Release Properties

Customers enjoy access to PFIs that can be developed to provide release properties, similar to brand leaders. This makes it possible for Finished Dosage manufacturers to get favorable outcomes from their bioequivalence studies.

Develops Dry-bending with other APIs

Develops Dry-bending with other APIs

We can design certain PFIs to be dry-blended with other APIs, without further granulation to obtain homogeneous mixtures. This helps make Finished Dosage forms of controlled substances, in combination with other APIs.